摘要
Abstract
OBJECTIVE:To probe into the Efficacy of oxycodone hydrochloride sustained release tablets in the treatment of cancer pain. METHODS: 195 patients with moderate cancer pain admitted into the First Affiliated Hospital of Qiqihar Medical University from Mar. 2017 to Mar. 2018 were selected and divided into observation group (63 cases), control group 1 (67 cases) and control group 2 (65 cases) via random number table. The observation group was given 10 mg of Oxycodone hydrochloride sustained-release tablets once every 12 h; the control group was treated with 30-60 mg of Bucinnazine hydrochloride tablets once every 8 h, with gradually increasing dosage when pain aggravation or drug resistance; the control group 2 was treated with 50-100 mg of Tramadol hydrochloride tablets, once every 8-12 h, with gradually increasing dosage when pain aggravation or drug resistance; patients in control group 1 and 2 were given 10-20 mg of oxycodone hydrochloride sustained-release tablets once every 12 h when they were in severe pain. Clinical efficacy and incidences of adverse drug reactions of patients with moderate and severe pain among three groups were observed. RESULTS: The total effective rate of patients with moderate pain in observation group was 79.4％ (50/63), which was significantly higher than than those of control group 1 (64.2％, 43/67) and control group 2 (52.3％, 34/65), with extremely statistically significant differences (P＜0.01); the total effective rates of patients with severe pain in observation group, control group 1 and control group 2 were respectively 67.8％ (40/59), 67.2％ (41/61) and 66.7％ (42/63), the differences had no statistical significance (P＞0.05); at moderate pain stage, the incidences of adverse drug reactions of observation group, control group 1 and control group 2 were respectively 36.5％ (23/63), 37.3％ (25/67) and 38.5％ (25/65), the differences had no statistical significance (P＞0.05); at severe pain stage, the incidences of adverse drug reactions of observation group, control group 1 and control group 2 were respectively 44.1％ (26/59), 45.9％ (28/61) and 42.9％ (27/63), the differences had no statistical significance (P＞0.05). CONCLUSIONS: Oxycodone hydrochloride sustained release tablets were used to weaken the two-step treatment, can effectively control pain for moderate cancer, with few adverse drug reactions, which is in favor of improving patients' life quality.关键词
弱化/二阶梯用药/三阶梯用药/癌性疼痛Key words
Weakening/Two-step medication/Three-step medication/Cancer pain分类
医药卫生
